Chongqing Evaheart Medical Device Co., Ltd has reportedly secured close to USD 100 million in a Series A financing round. The round was led by Sinovac, with significant contributions from Taiping (Shenzhen) Healthcare Industry Private Equity Investment Fund and Vivo Capital. The funds raised will be directed towards the development and construction of a comprehensive heart failure treatment platform.
Company Overview and Product Highlights
Evaheart Med, established in 2014, is an industry-leading platform dedicated to heart failure. The company offers full lifecycle solutions that cover prevention, diagnosis, monitoring, treatment, and end-stage assistance. A standout product in their portfolio is the implantable left ventricular assist device, EVAHEART, which is acclaimed as the first artificial heart in China. This pioneering product has garnered approvals in Europe and Japan and has recently obtained Investigational Device Exemption (IDE) approval in the United States, marking a significant milestone in its global expansion.-Fineline Info & Tech
